gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ARCTHealthcarePharmaceuticals

Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)

$10.87+13.94%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$10.87▲ 21.72% in range
Nov 4, 2025Low $5.53 · High $16.93Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Arcturus Therapeutics Holdings closed at $10.87 on Nov 4, up 13.94%, 35.8% below its 52-week closing high. Volume of 496.0K shares was 0.73× its 20-day average (below normal).

Split-adjusted performance: -16.4% over one month, +19.1% over six months, +16.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $2.96M, down 89.5% from a year earlier, with a net margin of -803.8%.

Short interest was 5.5M shares at the Oct 15 settlement, up 1.5% from the prior report (24.0% of float, 8.4 days to cover).

Market cap$309.0M28.4M shares
Revenue · quarter$3.0M−89.5% YoY
Diluted EPS$-0.84—
P/E · TTM—P/S 10.5×
Net margin-803.8%Gross 100.0%
Dividend yieldNone
52-week range5.53 – 16.93−35.8% from high
Volume496.0K0.73× 20-day avg
Volatility · 60d114.4%Annualised
Short % of float24.0%8.4 days to cover
Net cash$191.5MCash $191.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.9%1M −16.4%3M +78.8%6M +19.1%YTD +77.3%1Y +16.9%3Y −41.7%5Y −76.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum81
Revenue growth13
Net margin24
Value (low P/E)—
Size54

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.5M+1.5% vs prior
Days to cover8.4Settled Oct 15
% of float24.0%
Short vol. 10d57.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ARCTArcturus Therapeutics Holdings$10.87+13.94%+19.1%−89.5%−803.8%—$309.0M
CYPHCypherpunk Technologies$2.87+10.38%+154.0%———$309.3MCompare
ENTAEnanta Pharmaceuticals$10.65+2.70%−30.1%−21.6%−135.8%—$310.2MCompare
SPRYARS Pharmaceuticals$3.050.00%−67.1%+114.2%−185.2%—$303.3MCompare
EBSEmergent Biosolutions$5.90−5.60%−35.2%−52.4%−29.7%—$302.5MCompare
CGCCanopy Growth$0.7517+6.37%−34.6%+7.8%−18.0%—$318.0MCompare
TTRXTurn Therapeutics$9.80+3.05%+158.2%———$297.6MCompare
BNTCBenitec Biopharma$9.28+10.48%−26.2%———$323.8MCompare
PRLDPrelude Therapeutics Incorporated$4.08+7.94%−15.7%—−244.1%—$325.6MCompare

News about Arcturus Therapeutics Holdings

All news →
mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and MoreGlobeNewswire Inc. · Aug 26, 2026Neutral

Quick answers

What does Arcturus Therapeutics Holdings do?
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines.
What is ARCT's market cap?
$308.96M, based on the Nov 4 close of $10.87.
Does Arcturus Therapeutics Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ARCT is sold short?
5.5M shares, 24.0% of float, as of Oct 15, 2026.
What sector is ARCT in?
Healthcare, in the Pharmaceuticals industry.

About Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

HQ: San Diego, CA111 employeesListed May 22, 2013arcturusrx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology